Search

Eugene W Gerner

from Tucson, AZ
Age ~77
Get Report
Also known as:
Eugene Dr Gerner, Eugene Willard Gerner, Gene W Gerner, Ugene Gerner
Phone and address:
1780 Sunset Rd, Tucson, AZ 85704
(520) 888-6719
Related to:
Joe W Stieber, 58Sandra E Gerner, 77Erica L Herman, 50Devin E Ballesteros, 35Jewell M EberleinDevin E Ballesteros, 59Arthur G EberleinDavid J Ballesteros, 59Stephanie L Ballesteros, 57David J Ballesteros, 57Sandra GernerCamren N Gerner, 37
Connected to:
Andre S Gerner, 33Gregor Gerner, 100Irina M Gerner, 72Jason C Gerner, 49Jerold S Gerner, 71Jon A Gerner, 62Nichole A Gerner, 42Pattie Gerner, 73Rick L Gerner, 66Samantha L Gerner, 45

Eugene Gerner Phones & Addresses

  • 1780 Sunset Rd, Tucson, AZ 85704 (520) 888-6719

Resumes

Resumes

Eugene Gerner Photo 1

Chief Scientific Officer, Board Member, Co-Founder

View page
Location:
Tucson, AZ
Industry:
Higher Education
Work:
The University of Arizona Tucson Apr 1974 - Mar 2014
Professor of Cellular and Molecular Medicine
Cancer Prevention Pharmaceuticals Apr 1974 - Mar 2014
Chief Scientific Officer, Board Member, Co-Founder
The University of Arizona Apr 1974 - Mar 2014
Professor Emeritus
Skills:
Lecturing
University Teaching
Program Evaluation
Theory
Curriculum Development
Courses
Academic Administration
Physics
Distance Learning
Curriculum Design
Eugene Gerner Photo 2

Chief Scientific Officer

View page
Location:
Tucson, AZ
Industry:
Pharmaceuticals
Work:
The University of Arizona Apr 1974 - Mar 2014
Professor
Cancer Prevention Pharmaceuticals Apr 1974 - Mar 2014
Chief Scientific Officer
Skills:
Clinical Trials
Molecular Biology
Biotechnology
Biochemistry
Drug Discovery
Pharmaceutical Industry
Lifesciences
Clinical Development
Oncology
Biomarkers
Protein Chemistry
Pharmacology
Life Sciences
Cell Biology
Drug Development
Microsoft Office
Regulatory Affairs
Cancer

Business Records

Name / Title
Company / Classification
Phones & Addresses
Eugene W Gerner
Manager
GERNER PHARMACEUTICAL INVESTORS, LLC
1780 W Sunset Rd, Tucson, AZ 85704

Publications

Us Patents

Hyperthermic Inducible Expression Vectors For Gene Therapy And Methods Of Use Thereof

View page
US Patent:
6709858, Mar 23, 2004
Filed:
Nov 3, 1998
Appl. No.:
09/185243
Inventors:
Tom Tsang - Tucson AZ
Eugene W. Gerner - Tucson AZ
David T. Harris - Tucson AZ
Evan Hersh - Tucson AZ
Assignee:
The Arizona Board of Regents on behalf of The University of Arizona - Tucson AZ
International Classification:
C12N 1585
US Classification:
4353201, 435 691, 435455, 435456, 435458, 424 932, 514 44
Abstract:
Methods and compositions are provided for transgene expression in target cells. Expression constructs using an inducible amplification system to drive expression of a therapeutic gene or other gene of interest in mammalian host cells are provided, as well as methods therefor. Inducible expression of the transgenes at high levels under physiologic conditions results from induction by hyperthermic conditions relative to the basal temperature of the host cells.

Inducible Expression Vectors And Methods Of Use Thereof

View page
US Patent:
7056897, Jun 6, 2006
Filed:
May 23, 2002
Appl. No.:
10/152577
Inventors:
Thomas Chun-Chang Tsang - Tucson AZ, US
Eugene W. Gerner - Tucson AZ, US
David T. Harris - Tucson AZ, US
Evan Hersh - Tucson AZ, US
Farha Vasanwala - Needham MA, US
Assignee:
The Arizona Board of Regents - Tucson AZ
International Classification:
A61K 48/00
C12N 15/85
C12N 15/86
US Classification:
514 44, 424 932, 4353201, 435455, 435456, 435458
Abstract:
The present invention relates to inducible gene expression constructs and methods of inducing gene expression using a combination of inducing agents.

Hyperthermic Inducible Expression Vectors For Gene Therapy And Methods Of Use Thereof

View page
US Patent:
7098191, Aug 29, 2006
Filed:
Mar 29, 2002
Appl. No.:
10/108486
Inventors:
Tom Tsang - Tuscon AZ, US
Eugene W. Gerner - Tucson AZ, US
David T. Harris - Tucson AZ, US
Evan Hersh - Tucson AZ, US
Assignee:
The Arizona Board of Reagents - Tucson AZ
International Classification:
A61K 48/00
C12N 1/21
C12N 5/10
C12N 15/67
C12N 15/79
US Classification:
514 44, 424 932, 424 9321, 4353201, 435 691, 435455, 435456, 435458, 4352523
Abstract:
Expression constructs using an inducible amplification system to drive expression of a therapeutic gene or other genes of interest in mammalian cells are provided, as well as methods of using the same.

Hyperthermic Inducible Expression Vectors For Gene Therapy And Methods Of Use Thereof

View page
US Patent:
7285542, Oct 23, 2007
Filed:
Dec 12, 2003
Appl. No.:
10/733280
Inventors:
Tom Tsang - Tucson AZ, US
Eugene W. Gerner - Tucson AZ, US
David T. Harris - Tucson AZ, US
Evan Hersh - Tucson AZ, US
Assignee:
The Arizona Board of Regents on behalf of The University of Arizona - Tucson AZ
International Classification:
A61K 48/00
C12N 15/85
C12N 15/86
US Classification:
514 44, 424 932, 4353201, 435455, 435456, 435458
Abstract:
Methods and compositions are provided for transgene expression in target cells. Expression constructs using an inducible amplification system to drive expression of a therapeutic gene or other gene of interest in mammalian host cells are provided, as well as methods therefor. Inducible expression of the transgenes at high levels under physiologic conditions results from induction by hyperthermic conditions relative to the basal temperature of the host cells.

Carcinoma Diagnosis And Treatment, Based On Odc1 Genotype

View page
US Patent:
8329636, Dec 11, 2012
Filed:
May 14, 2010
Appl. No.:
12/780592
Inventors:
Eugene Gerner - Tucson AZ, US
Jason A. Zell - Dana Point CA, US
Christine McLaren - Irvine CA, US
Frank Meyskens - Irvine CA, US
Hoda Anton-Culver - Irvine CA, US
Patricia A. Thompson - Tucson AZ, US
Assignee:
Arizona Board of Regents on Behalf of University of Arizona - Tucson AZ
The Regents of the University of California, a California Corporation - Oakland CA
International Classification:
A01N 61/00
US Classification:
514 1
Abstract:
The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.

Alpha-Difluoromethylornithine (Dfmo) Suppresses Polyamine Levels In The Human Prostate

View page
US Patent:
20020137797, Sep 26, 2002
Filed:
Aug 24, 2001
Appl. No.:
09/938846
Inventors:
Frank Meyskens - Irvine CA, US
Anne Simoneau - Long Beach CA, US
Eugene Gerner - Tucson AZ, US
International Classification:
A61K031/198
US Classification:
514/564000
Abstract:
The present invention concerns a method for treating and/or inhibiting prostate cancer in a patient comprising administering -difluoromethylornithine (DFMO) in an amount and duration sufficient to stabilize or reduce the amount of polyamine produced by the hyperplastic cells, wherein said polyamine is spermine, spermidine or a combination of spermine and spermidine. Methods of administration, dosing, and combinational therapies are described.

Alpha-Difluoromethylornithine(Dfmo) Suppresses Polyamine Levels In The Human Prostate

View page
US Patent:
20040162353, Aug 19, 2004
Filed:
Feb 17, 2004
Appl. No.:
10/780921
Inventors:
Frank Meyskens - Irvine CA, US
Anne Simoneau - Long Beach CA, US
Eugene Gerner - Tucson AZ, US
International Classification:
A61K031/198
US Classification:
514/564000
Abstract:
The present invention concerns a method for treating and/or inhibiting prostate cancer in a patient comprising administering -difluoromethylornithine (DFMO) in an amount and duration sufficient to stabilize or reduce the amount of polyamine produced by the hyperplastic cells, wherein said polyamine is spermine, spermidine or a combination of spermine and spermidine. Methods of administration, dosing, and combinational therapies are described.

Cancer Prevention And Treatment Methods Based On Dietary Polyamine Content

View page
US Patent:
20130217743, Aug 22, 2013
Filed:
May 13, 2011
Appl. No.:
13/697984
Inventors:
Kavitha P. Raj - Pleasanton CA, US
Jason A. Zell - Dana Point CA, US
Christine E. Mclaren - Irvine CA, US
Eugene W. Gerner - Tucson AZ, US
Jeffrey Jacob - Tucson AZ, US
Assignee:
CANCER PREVENTION PHARMACEUTICALS, INC. - Tucson AZ
CANCER PREVENTION PHARMACEUTICAL, INC - Tucson AZ
THE REGENT OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION - Oakland CA
International Classification:
A61K 31/198
A61K 31/415
A61K 31/192
US Classification:
514406, 514564
Abstract:
Controlling exogenous polyamines may be used, in some aspects, as an adjunctive strategy to chemoprevention with polyamine inhibitory agents, for example, anti-carcinoma combination therapies comprising ornithine decarboxylase (ODC) inhibitor and a spermidine/spermine N-acetyltransferase expression agonist, optionally based on a patient's ODC1 promoter genotype. Assessing a tissue polyamine level or tissue polyamine flux may be used in some aspects, for predicting the efficacy of an anti-carcinoma combination therapy comprising, for example, an ornithine decarboxylase (ODC) inhibitor and an agent that modulates the polyamine pathway to reduce overall cellular polyamine content.
Control profile
Eugene W Gerner from Tucson, AZ, age ~77 Get Report